The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2021 | Risk stratification for CTCL
Lauren Pinter-Brown, MD, of UCI Health, Chao Family Comprehensive Cancer Center, Orange, CA, discusses the debate around risk stratification for cutaneous T-cell lymphoma (CTCL) based on the diagnosis, the stage of disease, and other presentations of the disease, as well as existing prototype registries including PROCLIPI. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
